Johnson & Johnson (NYSE:JNJ) Shares Acquired by River Wealth Advisors LLC

River Wealth Advisors LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,906 shares of the company’s stock after acquiring an additional 111 shares during the period. River Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $3,516,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Glassy Mountain Advisors Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $35,000. Retirement Financial Solutions LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $40,000. TD Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter valued at approximately $48,000. VitalStone Financial LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth $52,000. Finally, Iron Horse Wealth Management LLC increased its position in Johnson & Johnson by 112.8% in the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after buying an additional 159 shares during the period. 67.94% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.20% of the company’s stock.

Johnson & Johnson Trading Down 1.4 %

Shares of NYSE JNJ opened at $154.41 on Friday. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $183.35. The company has a market cap of $401.27 billion, a price-to-earnings ratio of 32.30, a P/E/G ratio of 2.67 and a beta of 0.53. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. The business has a fifty day simple moving average of $159.89 and a 200-day simple moving average of $165.86.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.51 by $0.17. The firm had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The business’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period in the prior year, the business earned $2.67 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be paid a $1.19 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a yield of 3.08%. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is currently 99.58%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on JNJ shares. Raymond James dropped their target price on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 19th. UBS Group initiated coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target for the company. Guggenheim initiated coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target for the company. StockNews.com initiated coverage on Johnson & Johnson in a research note on Thursday, May 18th. They issued a “strong-buy” rating for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $173.00.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.